FindTrial
Sign In

Pre-operative application of Teltivudine to improve hepatic function in patients with Primary hepatic cancer and positive HBV-DNA of low-concentration

Pre-operative application of Teltivudine to improve hepatic function in patients with Primary hepatic cancer and positive HBV-DNA of low-concentration

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-09000615
Enrollment
Unknown
Registered
2009-12-10
Start date
2009-10-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary liver cancer (hepatic cell carcinoma, HCC)

Interventions

Group A:Telbivudine was given before operation
Group B:no antivirus drug before operation

Sponsors

East hepatobiliary hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Male and female aged 18 to 70 years old; 2. Able and willing to provide signed informed consent; 3. HCC patients diagnosed by clinical manifestation with low-consentration positive HBV-DNA (1000 copy/ml- 100000 copy/ml in HBsAg Positive and HBeAg Positive patients, 1000 copy/ml- 10000 copy/ml in HBsAg Positive and HBeAg Negativetive patients); 4. Normal liver function or ALT or AST was less than twice normal value.

Exclusion criteria

Exclusion criteria: 1. Liver function: Child-Pugh B and C; 2. Patients with severe heart or renal or blood disease; 3. Patients with alergic history; 4. Pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
HBV-DNA concentration;—

Secondary

MeasureTime frame
Liver function;—

Countries

China

Contacts

Public ContactJingjian Sun
sunjingjian@21cn.com+86 13701916217

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026